Publications


Simonin C, Duru C, Salleron J, Hincker P, Charles P, Delval A, Youssov K, Burnouf S, Azulay JP, Verny C, Scherer C, Tranchant C, Goizet C, Debruxelles S, Defebvre L, Sablonnière B, Romon-Rousseaux M, Buée L, Destée A, Godefroy O, Dürr A, Landwehrmeyer B;REGISTRY Study of the European Huntington’s Disease Network,Bachoud-Levi AC, Richard F, Blum D, Krystkowiak P
On behalf the Huntington French Speaking Network Association between caffeine intake and age at onset in Huntington’s disease.
Association between caffeine intake and age at onset in Huntington’s disease.
Neurobiol Dis. 2013 May 31;58C:179-182.


Carrière N, Kreisler A, Dujardin K, Destée A, Defebvre L.
[Impulse control disorders in Parkinson’s disease: A cohort of 35 patients].
Rev Neurol (Paris). 2012 Feb;168(2):143-51.


Chartier-Harlin MC, Dachsel JC, Vilariño-Güell C, Lincoln SJ, Leprêtre F, Hulihan MM, Kachergus J, Milnerwood AJ, Tapia L, Song MS, Le Rhun E, Mutez E, Larvor L, Duflot A, Vanbesien-Mailliot C, Kreisler A, Ross OA, Nishioka K, Soto-Ortolaza AI, Cobb SA, Melrose HL, Behrouz B, Keeling BH, Bacon JA, Hentati E, Williams L, Yanagiya A, Sonenberg N, Lockhart PJ, Zubair AC, Uitti RJ, Aasly JO, Krygowska-Wajs A, Opala G, Wszolek ZK, Frigerio R, Maraganore DM, Gosal D, Lynch T, Hutchinson M, Bentivoglio AR, Valente EM, Nichols WC, Pankratz N, Foroud T, Gibson RA, Hentati F, Dickson DW, Destée A, Farrer MJ.
Translation initiator EIF4G1 mutations in familial Parkinson disease.
Am J Hum Genet. 2011 Sep 9;89(3):398-406.
http://www.inserm.fr/espace-journalistes/decouverte-d-un-nouveau-gene-dont-les-mutations-sont-associees-a-la-maladie-de-parkinson


Ross OA, Soto-Ortolaza AI, Heckman MG, Aasly JO, Abahuni N, Annesi G, Bacon JA, Bardien S, Bozi M, Brice A, Brighina L, Van Broeckhoven C, Carr J, Chartier-Harlin MC, Dardiotis E, Dickson DW, Diehl NN, Elbaz A, Ferrarese C, Ferraris A, Fiske B, Gibson JM, Gibson R, Hadjigeorgiou GM, Hattori N, Ioannidis JP, Jasinska-Myga B, Jeon BS, Kim YJ, Klein C, Kruger R, Kyratzi E, Lesage S, Lin CH, Lynch T, Maraganore DM, Mellick GD, Mutez E, Nilsson C, Opala G, Park SS, Puschmann A, Quattrone A, Sharma M, Silburn PA, Sohn YH, Stefanis L, Tadic V, Theuns J, Tomiyama H, Uitti RJ, Valente EM, van de Loo S, Vassilatis DK, Vilariño-Güell C, White LR, Wirdefeldt K, Wszolek ZK, Wu RM, Farrer MJ.
Genetic Epidemiology Of Parkinson’s Disease (GEO-PD) Consortium.
Association of LRRK2 exonic variants with susceptibility to Parkinson’s disease: a case-control study.
Lancet Neurol. 2011 Oct;10(10):898-908.


Sharma M, Maraganore DM, Ioannidis JP, Riess O, Aasly JO, Annesi G, Abahuni N, Bentivoglio AR, Brice A, Van Broeckhoven C, Chartier-Harlin MC, Destée A, Djarmati A, Elbaz A, Farrer M, Ferrarese C, Gibson JM, Gispert S, Hattori N, Jasinska-Myga B, Klein C, Lesage S, Lynch T, Lichtner P, Lambert JC, Lang AE, Mellick GD, De Nigris F, Opala G, Quattrone A, Riva C, Rogaeva E, Ross OA, Satake W, Silburn PA, Theuns J, Toda T, Tomiyama H, Uitti RJ, Wirdefeldt K, Wszolek Z, Gasser T, Krüger R; Genetic Epidemiology of Parkinson’s Disease Consortium.
Role of sepiapterin reductase gene at the PARK3 locus in Parkinson’s disease.
Neurobiol Aging. 2011 Nov;32(11):2108.e1-5.


Mutez E, Leprêtre F, Le Rhun E, Larvor L, Duflot A, Mouroux V, Kerckaert JP, Figeac M, Dujardin K, Destée A, Chartier-Harlin MC. SNCA locus duplication carriers: from genetics to Parkinson disease phenotypes. Hum Mutat. 2011 Apr;32(4):E2079-90.

Elbaz A, Ross OA, Ioannidis JP, Soto-Ortolaza AI, Moisan F, Aasly J, Annesi G, Bozi M, Brighina L, Chartier-Harlin MC, Destée A, Ferrarese C, Ferraris A, Gibson JM, Gispert S, Hadjigeorgiou GM, Jasinska-Myga B, Klein C, Krüger R, Lambert JC, Lohmann K, van de Loo S, Loriot MA, Lynch T, Mellick GD, Mutez E, Nilsson C, Opala G, Puschmann A, Quattrone A, Sharma M, Silburn PA, Stefanis L, Uitti RJ, Valente EM, Vilariño-Güell C, Wirdefeldt K, Wszolek ZK, Xiromerisiou G, Maraganore DM, Farrer MJ; Genetic Epidemiology of Parkinson’s Disease (GEO-PD) Consortium.
Independent and joint effects of the MAPT and SNCA genes in Parkinson disease.
Ann Neurol. 2011 May;69(5):778-92


Mutez E, Larvor L, Leprêtre F, Mouroux V, Hamalek D, Kerckaert JP, Pérez-Tur J, Waucquier N, Vanbesien-Mailliot C, Duflot A, Devos D, Defebvre L, Kreisler A, Frigard B, Destée A, Chartier-Harlin MC.
Transcriptional profile of Parkinson blood mononuclear cells with LRRK2 mutation.
Neurobiol Aging. 2011 Oct;32(10):1839-48.


Krüger R, Sharma M, Riess O, Gasser T, Van Broeckhoven C, Theuns J, Aasly J, Annesi G, Bentivoglio AR, Brice A, Djarmati A, Elbaz A, Farrer M, Ferrarese C, Gibson JM, Hadjigeorgiou GM, Hattori N, Ioannidis JP, Jasinska-Myga B, Klein C, Lambert JC, Lesage S, Lin JJ, Lynch T, Mellick GD, de Nigris F, Opala G, Prigione A, Quattrone A, Ross OA, Satake W, Silburn PA, Tan EK, Toda T, Tomiyama H, Wirdefeldt K, Wszolek Z, Xiromerisiou G, Maraganore DM; Genetic Epidemiology of Parkinson’s disease consortium.
A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson’s disease.
Neurobiol Aging. 2011 Mar;32(3):548.e9-18.


Kreisler A, Duhamel A, Vanbesien-Mailliot C, Destée A, Bordet R.
Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson’s disease.
Behav Pharmacol
. 2010 May;21(3):194-205.


Destée A, Mutez E, Kreisler A, Vanbesien-Maillot C, Chartier-Harlin MC.
[Parkinson disease: genetics and neuronal death].
Rev Neurol (Paris). 2009 Apr;165 Spec No 2:F80-5. Review.

 

Vilariño-Güell C, Wider C, Soto-Ortolaza AI, Cobb SA, Kachergus JM, Keeling BH, Dachsel JC, Hulihan MM, Dickson DW, Wszolek ZK, Uitti RJ, Graff-Radford NR, Boeve BF, Josephs KA, Miller B, Boylan KB, Gwinn K, Adler CH, Aasly JO, Hentati F, Destée A, Krygowska-Wajs A, Chartier-Harlin MC, Ross OA, Rademakers R, Farrer MJ.
Characterization of DCTN1 genetic variability in neurodegeneration.
Neurology. 2009 Jun 9;72(23):2024-8.


Mutez E, Duhamel A, Defebvre L, Bordet R, Destée A, Kreisler A.
Lipid-lowering drugs are associated with delayed onset and slower course of Parkinson’s disease.
Pharmacol Res
. 2009 Jul;60(1):41-5


Simonin C, Tir M, Devos D, Kreisler A, Dujardin K, Salleron J, Delval A, Blond S, Defebvre L, Destée A, Krystkowiak P.
Reduced levodopa-induced complications after 5 years of subthalamic stimulation in Parkinson’s disease: a second honeymoon.
J Neurol. 2009 Oct;256(10):1736-41


Dujardin K, Sockeel P, Delliaux M, Destée A, Defebvre L.
Apathy may herald cognitive decline and dementia in Parkinson’s disease.
Mov Disord. 2009 Dec 15;24(16):2391-7.

 

Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E; ADAGIO Study Investigators (Destee).
A double-blind, delayed-start trial of rasagiline in Parkinson’s disease.
N Engl J Med. 2009 Sep 24;361(13):1268-78


Devos D, Moreau C, Destée A.
Levodopa for Parkinson’s disease.

N Engl J Med
. 2009 Feb 26;360(9):935-6

 

Laloux C, Derambure P, Kreisler A, Houdayer E, Bruezière S, Bordet R, Destée A, Monaca C.
MPTP-treated mice: long-lasting loss of nigral TH-ir neurons but not paradoxical sleep alterations.
Exp Brain Res
. 2008 Apr;186(4):635-42.


Ross OA, Braithwaite AT, Skipper LM, Kachergus J, Hulihan MM, Middleton FA, Nishioka K, Fuchs J, Gasser T, Maraganore DM, Adler CH, Larvor L, Chartier-Harlin MC, Nilsson C, Langston JW, Gwinn K, Hattori N, Farrer MJ.
Genomic investigation of alpha-synuclein multiplication and parkinsonism.
Ann Neurol.
2008 Jun;63(6):743-50.


Simonin C, Devos D, Vuillaume I, de Martinville B, Sablonnière B, Destée A, Stoppa-Lyonnet D, Defebvre L.
Attenuated presentation of ataxia-telangiectasia with familial cancer history.
J Neurol. 2008 Aug;255(8):1261-3.

 

Vanbesien-Mailliot CC, Wolowczuk I, Mairesse J, Viltart O, Delacre M, Khalife J, Chartier-Harlin MC, Maccari S.
Prenatal stress has pro-inflammatory consequences on the immune system in adult rats.
Psychoneuroendocrinology. 2007 Feb;32(2):114-24.


Vidailhet M, Vercueil L, Houeto JL, Krystkowiak P, Lagrange C, Yelnik J, Bardinet E, Benabid AL, Navarro S, Dormont D, Grand S, Blond S, Ardouin C, Pillon B, Dujardin K, Hahn-Barma V, Agid Y, Destée A, Pollak P
French SPIDY Study Group.

Bilateral, pallidal, deep-brain stimulation in primary generalised dystonia: a prospective 3 year follow-up study.

Lancet Neurol. 2007 Mar;6(3):223-9.